REG - ValiRx PLC - Collaborative Services Agreement

ValiRxAnnouncement

26/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230426:nRSZ4433Xa&default-theme=true

RNS Number : 4433X  ValiRx PLC  26 April 2023

ValiRx PLC

("ValiRx" or the "Company")

Collaborative Services Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces that the
Company's wholly owned subsidiary, Inaphaea BioLabs Limited ("Inaphaea"), has
entered into a collaborative services agreement with Physiomics plc (AIM:PYC)
("Physiomics") ("Collaborative Services Agreement").

The Collaborative Services Agreement recognises the synergy between Inaphaea's
growing capabilities as a translational contract research organisation
(tCRO®) and Physiomics' capabilities for advanced statistical analyses,
machine learning techniques, data handling and visualisation, as well as
biological modelling.

Under the agreement, service users of Inaphaea will be able to benefit from
Physiomics capabilities in a single service contract with Inaphaea.  Designed
to offer a seamless integration of data generation and data interpretation,
this collaborative method of working provides benefits to both companies as
well as to the service users.

Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is
the first step towards converting Inaphaea into a full service tCRO®.  The
Physiomics modelling skills will enable our clients to interpret and build on
the data generated within the Inaphaea facility.  I am delighted to be able
to offer this additional service module to our clients.  This additional
value-added service will be available to our first service users, with
benefits expected to increase as more complex data generation technologies are
added to our capabilities."

Dr Jim Millen, CEO at Physiomics commented "The Collaborative Services
Agreement will expand the scope of our core consulting business to discovery
stage projects and improve our access to clients focused on earlier stages of
drug development, while at the same time supporting Inaphaea's own service
offering.  The synergy is clear and both the scientific and commercial
ambitions of our two companies are well matched.  We look forward to working
closely with ValiRx through this initiative."

 

The Directors of the Company take responsibility for this announcement.

 

For more information, please contact:

 

 ValiRx plc                                                     Tel: +44 (0) 2476 796496

                                                                www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                          Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Inaphaea BioLabs Limited                                       www.inaphaea.com (http://www.inaphaea.com/)

 Dr Andrew Carnegie, Head of Strategic Commercial Development   Andrew.Carnegie@inaphaea.com (mailto:Andrew.Carnegie@inaphaea.com)

 V Formation (Public Relations)                                 +44 (0) 115 787 0206

                                                                www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                                            lucy@vformation.biz

                                                                sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)               Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)                           Tel: +44 (0) 20 7397 8900

 Russell Kerr/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)                         Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

Their approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

Through use of bespoke models and their proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 projects, over 40
targets and 70 drugs.  Physiomics' clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRSEAFMIEDSEIL